Timing of treatment shapes the path to androgen receptor signaling inhibitor resistance in prostate cancer
Eugine Lee(Memorial Sloan Kettering Cancer Center), Charles L. Sawyers(Memorial Sloan Kettering Cancer Center)
Cited by 1
Related Papers
The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway
|Proceedings of the National Academy of Sciences|1998|691
Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency
|Journal of Clinical Investigation|2007|415
Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives antiandrogen resistance in prostate cancer
|eLife|2017|215
GREB1 amplifies androgen receptor output in human prostate cancer and contributes to antiandrogen resistance
|eLife|2019|24
BRCA2 reversion mutation-independent resistance to PARP inhibition in prostate cancer through loss of function perturbations in the DNA pre-replication complex
|bioRxiv (Cold Spring Harbor Laboratory)|2025|1